Nimesil (Nimesulide)

Nimesulide, the active ingredient in Nimesil, is a NSAID presented as a 100 mg oral suspension for oral use. It provides symptomatic relief of pain, fever and inflammation and is prescribed for adults with conditions such as osteoarthritis and dysmenorrhea. It is indicated for short‑term management of acute musculoskeletal pain and menstrual cramps.

GNH USA supplies Nimesil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and delivers to a global network of healthcare facilities.

Nimesil (nimesulide) acts on inflammatory pathways to alleviate several common conditions. - Pain: provides symptomatic relief of mild to moderate pain. - Fever: reduces elevated body temperature associated with acute febrile states. - Inflammation: decreases inflammatory response in acute musculoskeletal conditions. - Osteoarthritis: alleviates joint pain and improves functional mobility in osteoarthritis. - Dysmenorrhea: eases menstrual pain and associated discomfort.

Nimesil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: reduced kidney function or acute renal failure. - Gastrointestinal ulcer or bleeding: serious bleeding events in the stomach or intestines.

Before prescribing Nimesil, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal function: assess baseline kidney status and monitor during therapy. - Hepatic function: check liver enzymes before initiation and periodically thereafter. - Gastrointestinal risk: use with caution in patients with a history of ulcer disease or bleeding. - Cardiovascular risk: avoid in uncontrolled hypertension or heart failure. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture.

Nimesil can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity. - Corticosteroids: additive risk of ulceration and bleeding. - Lithium: possible increase in lithium serum levels. - Methotrexate: enhanced toxicity, especially at high doses.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function. - Diuretics: potential for reduced renal perfusion. - Antihypertensives: possible attenuation of blood‑pressure control. - SSRIs: modest increase in bleeding tendency. - Oral hypoglycemics: may affect glucose control.